Candesartan versus Placebo for Migraine Prevention in Patients with Episodic Migraine: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
SSRN Electronic Journal2025
Lise Rystad Øie, Tore Wergeland, Oivind Salvesen, Gøril Bruvik Gravdahl, Irina Aschehoug, Sasha Gulati, Marte‐Helene Bjørk, Christofer Lundqvist, Karl Bjørnar Alstadhaug, Bendik S. Winsvold, Anne Hege Aamodt, Iben Cornelia Keim Larsen, M. Bo, Mark Braschinsky, Bernd Müller, Kjersti Grøtta Vetvik, Kai Ivar Müller, Kjersti Aaseth, Andrej Netland Khanevski, Ane Bakke Øvrevik, Håkon Magne Vegrim, Jenny Lindroos, Karine Eid, Helene Engstrand, Burcu Bezgal, M. Larsen, Joakim Høgsteggen Østhus, Lars Jacob Stovner, Erling Tronvik
Related Papers
- Candesartan cilexetil: a review of its preclinical pharmacology.(1997)
- → Clinical studies with candesartan(1999)5 cited
- → An Angiotensin II Type 1 Receptor Blocker, Candesartan, Increases Myocardial Apoptosis in Rats with Acute Ischemia-Reperfusion.(2001)12 cited
- → Transport proteins in the inner medullas of diabetic kidneys are further increased by candesartan.(2008)
- Transport characteristics of Candesartan and Candesartan cilexetil in Caco-2 cell model(2008)